Together we will beat cancer

Donate

Chemo before surgery helps stop colon cancer coming back

Giving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back, according to a trial we funded.

Read More

England slips further off-track for smokefree 2030 target

The UK government is almost a decade behind achieving its target for England to be smokefree by 2030, a new report reveals.

Read More

Cancer Research UK report highlights stark cancer inequalities across Scotland

A landmark report on deprivation and cancer launched at the Scottish Cancer Conference today shows that the burden of cancer is not felt equally across Scotland. 

Read More

First-of-its-kind app for patients on clinical trials being piloted by Cancer Research UK

Cancer Research UK, in partnership with tech company Stitch, are going live with an app for patients to use whilst participating in a clinical trial.  

Read More

NICE recommends pembrolizumab for 1,600 more people with breast cancer

The “potentially life-saving” immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

Read More

TRACERx EVO, a new programme to transform lung cancer research

Today, we’ve announced TRACERx EVO, a new programme that builds on the discoveries made in the world’s largest long-term lung study, TRACERx. 

Read More

A tribute to Dame Valerie Beral

Cancer Research UK would like to pay tribute to Dame Valerie Beral, whose research has contributed enormously to the field…

Read More

New treatment for Waldenstrom’s macroglobulinaemia in England

The National Institute for Health and Care Excellence (NICE) has recommended zanubrutinib (Brukinsa) as an option for treating some people…

Read More

Ending smoking could more than halve England’s cancer inequality gap

It’s known that people from more deprived backgrounds are more likely to get cancer. New analysis from Cancer Research UK…

Read More

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

Read More